Independent research on the U.S. markets, Baptista Research

Baptista Research

Independent research on the U.S. markets

Baptista Research is an independent financial research house focused on the U.S. markets. We provide equity research as well as credit research reports on the top-listed U.S. companies with most of our focus on technology, consumer goods and services, automobiles, industrials, oil and gas, pharma, and healthcare. Our research has served more than 3000 institutional investors including mutual funds, hedge funds, banks, family offices, and various buy-side firms. We operate a research subscription service where institutions, as well as retail investors, can have priority access to all our research. We also have a wide distribution of our research reports across some of the top global financial platforms. Apart from equity research and credit research, we also provide advisory services with respect to mergers & acquisitions (M&A), private equity/ venture capital fundraising, valuation reports, and investment management services for corporates.
Baptista Research is owned and managed by Ishan Majumdar, an ex-Venture Capitalist/ Investment Banker, a Chartered Accountant, and a Masters’ degree holder in Management from HEC Paris. Ishan has nearly a decade of experience in Mergers and Acquisitions, Leveraged Buyouts (LBOs), Venture Capital Investing, Corporate Strategy, and Valuation in front-office roles at the likes of BNP Paribas CIB, Credit Agricole CIB, Groupe Danone, and TIW Private Equity. He has worked on and closed multiple acquisition deals, leveraged buyouts, and start-up investment transactions.

Equity Bottom-Up

<ul><li>Viatris Inc.</li><li>reported its Q4 and Full Year 2023 Earnings with strong operational results, showing revenue growth for the third consecutive quarter.</li><li>As Viatris begins 2024, it continues to generate strong free cash flows that provide the flexibility to balance capital return to shareholders and strategic investments for future growth.</li></ul>

Viatris Inc.reported its Q4 and Full Year 2023 Earnings with strong operational results, showing revenue growth for the third consecutive quarter.As Viatris begins 2024, it continues to generate strong free cash flows that provide the flexibility to balance capital return to shareholders and strategic investments for future growth.

Viatris Inc.: Strategic Expansion Into Key Therapeutic Verticals & 6 Other Major Drivers

<ul><li>Viatris' results were a major disappointment as the company failed to meet Wall Street's revenue and earnings expectations.</li><li>During the third quarter, Viatris delivered total revenues of $3.94 billion, showcasing approximately 1% year-over-year growth, surpassing expectations with an adjusted EBITDA of $1.36 billion and free cash flow of $738 million.</li><li>In this report, we have carried out a fundamental analysis of the historical financial statements of the company.</li></ul>

Viatris' results were a major disappointment as the company failed to meet Wall Street's revenue and earnings expectations.During the third quarter, Viatris delivered total revenues of $3.94 billion, showcasing approximately 1% year-over-year growth, surpassing expectations with an adjusted EBITDA of $1.36 billion and free cash flow of $738 million.In this report, we have carried out a fundamental analysis of the historical financial statements of the company.

Viatris Inc.: The Blueprint for Conquering the Global Pharma Market! - Major Drivers

<ul><li>Viatris Inc. delivered mixed results for the previous quarter, with revenues above the analyst consensus.</li><li>The company exceeded its expectations in the quarter, delivering total revenues of $3.9 billion, or about 2% year-over-year growth on an operational adjusted basis, as well as adjusted EBITDA of $1.3 billion and free cash flow of $447 million.</li><li>Tyrvaya's bridge program was improved during the quarter to boost value per script and produce the greatest quarterly TRx launch.</li></ul>

Viatris Inc. delivered mixed results for the previous quarter, with revenues above the analyst consensus.The company exceeded its expectations in the quarter, delivering total revenues of $3.9 billion, or about 2% year-over-year growth on an operational adjusted basis, as well as adjusted EBITDA of $1.3 billion and free cash flow of $447 million.Tyrvaya's bridge program was improved during the quarter to boost value per script and produce the greatest quarterly TRx launch.

Viatris Inc.: Unveiling the Power of Popular Brands like Lipitor and Lyrica! - Major Drivers

<ul><li>Viatris' results were a major disappointment as the company failed to meet the revenue expectations as well as the earnings expectations of Wall Street.</li><li>The company achieved decent results in developed markets, with a full European version driven by critical brands and generics.</li><li>The company expects mid-single-digit growth in this segment, primarily driven by the brand category.</li></ul>

Viatris' results were a major disappointment as the company failed to meet the revenue expectations as well as the earnings expectations of Wall Street.The company achieved decent results in developed markets, with a full European version driven by critical brands and generics.The company expects mid-single-digit growth in this segment, primarily driven by the brand category.

Viatris Inc.: Emerging Market Growth Makes Up Disappointing Performance? – Key Drivers

<ul><li>Viatris delivered a mixed set of results as it failed to meet the revenue expectations of Wall Street but managed an earnings beat.</li><li>They dealt with intense competition for important products like Wixela and the loss of exclusivity for Miacalcin and Perforomist.</li><li>In addition, they acquired Oyster Point Pharma and Famy Life Sciences in January to create their new Viatris Eye Care division.</li></ul>

Viatris delivered a mixed set of results as it failed to meet the revenue expectations of Wall Street but managed an earnings beat.They dealt with intense competition for important products like Wixela and the loss of exclusivity for Miacalcin and Perforomist.In addition, they acquired Oyster Point Pharma and Famy Life Sciences in January to create their new Viatris Eye Care division.

United States

Viatris Inc. operates as a pharmaceutical company. The Company produces medicines for patients across broad range of major therapeutic areas spanning both noncommunicable and infectious diseases. Viatris serves clients worldwide.

Price Gauge
52-week Range	0.00 - 0.00
Market Cap (USDm)	0.00
P/E	0.00
Dividend (Yield)	0.00

Viatris (VTRS US)

Viatris Inc.: Strategic Expansion Into Key Therapeutic Verticals & 6 Other Major Drivers

Viatris Inc. reported its Q4 and Full Year 2023 Earnings with strong operational results, showing revenue growth for the third consecutive...

Baptista Research

Viatris Inc.: The Blueprint for Conquering the Global Pharma Market! - Major Drivers

Viatris' results were a major disappointment as the company failed to meet Wall Street's revenue and earnings expectations. During the third...

Baptista Research

Viatris Inc.: Unveiling the Power of Popular Brands like Lipitor and Lyrica! - Major Drivers

Viatris Inc. delivered mixed results for the previous quarter, with revenues above the analyst consensus. The company exceeded its expectations in...

Baptista Research

Viatris Inc.: Emerging Market Growth Makes Up Disappointing Performance? – Key Drivers

Viatris' results were a major disappointment as the company failed to meet the revenue expectations as well as the earnings expectations of Wall...

Baptista Research

Viatris Inc.: Major Drivers

Viatris delivered a mixed set of results as it failed to meet the revenue expectations of Wall Street but managed an earnings beat. They dealt...

Baptista Research

Price Gauge

52-week Range

Market Cap (USDm)

P/E

Dividend (Yield)